Advertisement

Annals of Hematology

, Volume 98, Issue 5, pp 1177–1184 | Cite as

Immunoparesis recovery 1 year after ASCT is independently associated with favorable survival in patients with symptomatic multiple myeloma who undergo autologous stem cell transplantation

  • Wen Gao
  • Jie Li
  • Yin Wu
  • Yanchen Li
  • Yun Leng
  • Aijun Liu
  • Guangzhong Yang
  • Ying Tian
  • Huijuan Wang
  • Guorong Wang
  • Zhipeng Wu
  • Zhangyong Ren
  • Wenming ChenEmail author
Original Article

Abstract

Immunoparesis is defined as a reduction in the levels of one, two, or three uninvolved immunoglobulins. However, there are very limited data on the incidence and prognostic significance of immunoparesis recovery 1 year after autologous stem cell transplantation (ASCT) in MM. We reviewed medical records of de novo MM patients who received ASCT at Beijing Chao Yang hospital. One hundred eight MM patients were included in the study. Conventional chemotherapy was administered as induction regimen in 16 patients (14.8%), whereas novel agents were used in 92 patients (85.2%). Most patients had immunoparesis at diagnosis (89.1%) and at the moment of ASCT as well (75%). After a median follow-up of 49 months, in the group with immunoglobulin recovery 1 year after ASCT, there was a trend towards longer progression-free survival (PFS) than in the group with immunoparesis (P = 0.054). And overall survival (OS) was significantly longer in patients with immunoparesis recovery (P = 0.004). In multivariate analysis, immunoparesis recovery 1 year after ASCT was independently associated with improved OS (P = 0.016). In conclusion, lack of immunoparesis recovery 1 year after ASCT in MM patients is associated with significantly shorter OS and this group of patients needs new treatment strategy to improve the prognosis.

Keywords

Multiple myeloma Immunoparesis Autologous stem cell transplantation 

Notes

Acknowledgments

The authors would like to thank for these MM patients in the study. We thank for Dr. Lirong Liang for critically reviewing the manuscript.

Authorship statement

W.G. collected and analyzed data and wrote the manuscript. J.L., G.Z.Y., Y.W., Y.C.L., Y.L., A.J.L., Y.T., H.J.W., G.R.W., T.H.H., Z.P.W., and Z.Y.R. contributed with treatment of patients and reviewed and approved the manuscript. W.M.C contributed with study design, data collection and interpretation, and manuscript writing.

Financial disclosure

This project was supported by grant and contract from basic and clinic research cooperation fund (grant 2015, 15JL37) and Students’ research innovation project (grant 2015, XSKY2015150) of Capital Medical University.

Compliance with ethical standards

Approval was obtained from the Institutional Review Board of Beijing Chao Yang Hospital for the analysis and publication of these data.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Alexanian R, Migliore PJ (1970) Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy. J Lab Clin Med 75(2):225–233Google Scholar
  2. 2.
    Kastritis E, Zagouri F, Symeonidis A, Roussou M, Sioni A, Pouli A, Delimpasi S, Katodritou E, Michalis E, Michael M, Hatzimichael E, Vassou A, Repousis P, Christophoridou A, Kartasis Z, Stefanoudaki E, Megalakaki C, Giannouli S, Kyrtsonis MC, Konstantopoulos K, Spyroupoulou-Vlachou M, Terpos E, Dimopoulos MA (2014) Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma. Leukemia 28(10):2075–2079.  https://doi.org/10.1038/leu.2014.110 CrossRefGoogle Scholar
  3. 3.
    Kawano M, Iwato K, Asaoku H, Tanabe O, Tanaka H, Ishikawa H, Kuramoto A (1989) Altered cytokine activities are related to the suppression of synthesis of normal immunoglobulin in multiple myeloma. Am J Hematol 30(2):91–96CrossRefGoogle Scholar
  4. 4.
    Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, Fonseca R, Rajkumar SV, Offord JR, Larson DR, Plevak ME, Therneau TM, Greipp PR (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78(1):21–33.  https://doi.org/10.4065/78.1.21 CrossRefGoogle Scholar
  5. 5.
    Peltonen S, Wasastjerna C, Wager O (1978) Clinical features of patients with a serum M component. Acta Med Scand 203(4):257–263Google Scholar
  6. 6.
    Pruzanski W, Gidon MS, Roy A (1980) Suppression of polyclonal immunoglobulins in multiple myeloma: relationship to the staging and other manifestations at diagnosis. Clin Immunol Immunopathol 17(2):280–286CrossRefGoogle Scholar
  7. 7.
    Katodritou E, Terpos E, Symeonidis AS, Pouli A, Kelaidi C, Kyrtsonis MC, Kotsopoulou M, Delimpasi S, Christoforidou A, Giannakoulas N, Viniou NA, Stefanoudaki E, Hadjiaggelidou C, Christoulas D, Verrou E, Gastari V, Papadaki S, Polychronidou G, Papadopoulou A, Giannopoulou E, Kastritis E, Kouraklis A, Konstantinidou P, Anagnostopoulos A, Zervas K, Dimopoulos MA (2014) Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patients. Am J Hematol 89(8):803–808.  https://doi.org/10.1002/ajh.23745 CrossRefGoogle Scholar
  8. 8.
    Perez-Persona E, Vidriales MB, Mateo G, Garcia-Sanz R, Mateos MV, de Coca AG, Galende J, Martin-Nunez G, Alonso JM, de Las Heras N, Hernandez JM, Martin A, Lopez-Berges C, Orfao A, San Miguel JF (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110(7):2586–2592.  https://doi.org/10.1182/blood-2007-05-088443 CrossRefGoogle Scholar
  9. 9.
    Ludwig H, Milosavljevic D, Berlanga O, Zojer N, Hubl W, Fritz V, Harding S (2016) Suppression of the noninvolved pair of the myeloma isotype correlates with poor survival in newly diagnosed and relapsed/refractory patients with myeloma. Am J Hematol 91(3):295–301.  https://doi.org/10.1002/ajh.24268 CrossRefGoogle Scholar
  10. 10.
    Rueff J, Medinger M, Heim D, Passweg J, Stern M (2014) Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant 20(6):896–899.  https://doi.org/10.1016/j.bbmt.2014.03.007 CrossRefGoogle Scholar
  11. 11.
    Hernandez MD, del Canizo MC, Gonzalez M, Caballero MD, Lopez-Berges MC, Vazquez L, Orfao A, Corral M, Nieto MJ, San Miguel JF (1998) Immune reconstitution after autologous progenitor hemopoietic cell transplantation. A study comparing autologous bone marrow and autologous peripheral blood transplantation. Med Clin 110(20):768–773Google Scholar
  12. 12.
    Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20(9):1467–1473.  https://doi.org/10.1038/sj.leu.2404284 CrossRefGoogle Scholar
  13. 13.
    Ross FM, Avet-Loiseau H, Ameye G, Gutierrez NC, Liebisch P, O'Connor S, Dalva K, Fabris S, Testi AM, Jarosova M, Hodkinson C, Collin A, Kerndrup G, Kuglik P, Ladon D, Bernasconi P, Maes B, Zemanova Z, Michalova K, Michau L, Neben K, Hermansen NE, Rack K, Rocci A, Protheroe R, Chiecchio L, Poirel HA, Sonneveld P, Nyegaard M, Johnsen HE (2012) Report from the European myeloma network on interphase FISH in multiple myeloma and related disorders. Haematologica 97(8):1272–1277.  https://doi.org/10.3324/haematol.2011.056176 CrossRefGoogle Scholar
  14. 14.
    Bradwell AR, Harding SJ, Fourrier NJ, Wallis GL, Drayson MT, Carr-Smith HD, Mead GP (2009) Assessment of monoclonal gammopathies by nephelometric measurement of individual immunoglobulin kappa/lambda ratios. Clin Chem 55(9):1646–1655.  https://doi.org/10.1373/clinchem.2009.123828 CrossRefGoogle Scholar
  15. 15.
    Bradwell A, Harding S, Fourrier N, Mathiot C, Attal M, Moreau P, Harousseau JL, Avet-Loiseau H (2013) Prognostic utility of intact immunoglobulin Ig'kappa/Ig'lambda ratios in multiple myeloma patients. Leukemia 27(1):202–207.  https://doi.org/10.1038/leu.2012.159 CrossRefGoogle Scholar
  16. 16.
    Gonzalez-Calle V, Cerda S, Labrador J, Sobejano E, Gonzalez-Mena B, Aguilera C, Ocio EM, Vidriales MB, Puig N, Gutierrez NC, Garcla-Sanz R, Alonso JM, Lopez R, Aguilar C, Garcla de Coca A, Hernandez R, Hernandez JM, Escalante F, Mateos MV (2017) Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma. Haematologica 102:922–931.  https://doi.org/10.3324/haematol.2016.158345 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Wen Gao
    • 1
  • Jie Li
    • 1
  • Yin Wu
    • 1
  • Yanchen Li
    • 1
  • Yun Leng
    • 1
  • Aijun Liu
    • 1
  • Guangzhong Yang
    • 1
  • Ying Tian
    • 1
  • Huijuan Wang
    • 1
  • Guorong Wang
    • 1
  • Zhipeng Wu
    • 1
  • Zhangyong Ren
    • 1
  • Wenming Chen
    • 1
    Email author
  1. 1.Department of Hematology, Myeloma Research Center of Beijing, Beijing Chao-Yang HospitalCapital Medical UniversityBeijingChina

Personalised recommendations